Ductal Carcinoma in Situ

Oncology
0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

GSK
GSKLONDON, United Kingdom
1 program
lapatinibN/ASmall Molecule1 trial
Active Trials
NCT00857714Terminated1Est. Aug 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKlapatinib

Clinical Trials (1)

Total enrollment: 1 patients across 1 trials

Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast

Start: Apr 2009Est. completion: Aug 20101 patients
N/ATerminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space